



## ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2024 - GENERELL INFORMASJON

### Enheten

Organisasjonsnummer: 986 400 990  
Organisasjonsform: Aksjeselskap  
Foretaksnavn: THERMO FISHER DIAGNOSTICS AS  
Forretningsadresse: Ullernchausséen 52  
0379 OSLO

### Regnskapsår

Årsregnskapets periode: 01.01.2024 - 31.12.2024

### Konsern

Morselskap i konsern: Nei

### Regnskapsregler

Regler for små foretak benyttet: Nei  
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

### Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Petrus Van Der Zande  
Dato for fastsettelse av årsregnskapet: 19.06.2025

### Grunnlag for avgivelse

År 2024: Årsregnskapet er elektronisk innlevert  
År 2023: Tall er hentet fra elektronisk innlevert årsregnskap fra 2024

*Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.*

Brønnøysundregistrene, 11.07.2025



### Resultatregnskap

Beløp i: NOK	Note	2024	2023
<b>RESULTATREGNSKAP</b>			
<b>Inntekter</b>			
Revenue from sales of products and services	2	126 185 000	132 903 000
<b>Sum inntekter</b>		<b>126 185 000</b>	<b>132 903 000</b>
<b>Kostnader</b>			
Raw materials and consumables used	3	102 238 000	109 055 000
Employee benefits expense	4	8 907 000	8 455 000
Depreciation and amortization expenses	5	1 147 000	347 000
Other operating expenses		8 899 000	12 134 000
<b>Sum kostnader</b>		<b>121 191 000</b>	<b>129 991 000</b>
<b>Driftsresultat</b>		<b>4 994 000</b>	<b>2 912 000</b>
<b>Finansinntekter og finanskostnader</b>			
Other intercompany finance income		1 736 000	1 406 000
<b>Sum finansinntekter</b>		<b>1 736 000</b>	<b>1 406 000</b>
Finance (expenses)		1 620 000	1 909 000
<b>Sum finanskostnader</b>		<b>1 620 000</b>	<b>1 909 000</b>
<b>Netto finans</b>		<b>116 000</b>	<b>-503 000</b>
<b>Resultat før skattekostnad</b>		<b>5 110 000</b>	<b>2 409 000</b>
Income tax expense	6	1 182 000	551 000
<b>Årsresultat</b>		<b>3 928 000</b>	<b>1 858 000</b>
<b>Overføringer og disponeringer</b>			
Transfers other equity	7	3 928 000	1 858 000
<b>Sum overføringer og disponeringer</b>		<b>3 928 000</b>	<b>1 858 000</b>



## Balanse

Beløp i: NOK	Note	2024	2023
<b>BALANSE - EIENDELER</b>			
<b>Anleggsmidler</b>			
<b>Immaterielle eiendeler</b>			
Utsatt skattefordel	6	14 197 000	15 379 000
<b>Sum immaterielle eiendeler</b>		<b>14 197 000</b>	<b>15 379 000</b>
<b>Varige driftsmidler</b>			
Operating equipment and other fixed assets	5	5 421 000	813 000
<b>Sum varige driftsmidler</b>		<b>5 421 000</b>	<b>813 000</b>
<b>Sum anleggsmidler</b>		<b>19 618 000</b>	<b>16 192 000</b>
<b>Omløpsmidler</b>			
<b>Varer</b>			
Inventories	8	818 000	292 000
<b>Sum varer</b>		<b>818 000</b>	<b>292 000</b>
<b>Fordringer</b>			
Accounts receivable		10 299 000	16 982 000
Other receivables		222 000	370 000
Konsernfordringer	10	19 804 000	34 447 000
<b>Sum fordringer</b>		<b>30 325 000</b>	<b>51 799 000</b>
<b>Bankinnskudd, kontanter og lignende</b>			
Cash and cash equivalents	12	3 606 000	4 278 000
<b>Sum bankinnskudd, kontanter og lignende</b>		<b>3 606 000</b>	<b>4 278 000</b>
<b>Sum omløpsmidler</b>		<b>34 749 000</b>	<b>56 369 000</b>
<b>SUM EIENDELER</b>		<b>54 367 000</b>	<b>72 561 000</b>

## BALANSE - EGENKAPITAL OG GJELD

### Egenkapital

#### Innskutt egenkapital



### Balanse

<b>Beløp i: NOK</b>	<b>Note</b>	<b>2024</b>	<b>2023</b>
Share capital	7, 11	100 000	100 000
Overkurs	7	200 000	200 000
<b>Sum innskutt egenkapital</b>		<b>300 000</b>	<b>300 000</b>
<b>Opptjent egenkapital</b>			
Retained equity	7	27 825 000	23 897 000
<b>Sum opptjent egenkapital</b>		<b>27 825 000</b>	<b>23 897 000</b>
<b>Sum egenkapital</b>		<b>28 125 000</b>	<b>24 197 000</b>
<b>Sum langsiktig gjeld</b>		<b>0</b>	<b>0</b>
<b>Kortsiktig gjeld</b>			
Trade payables		1 600 000	122 000
Other short-term debt		9 147 000	11 411 000
Payables to group companies	10	15 495 000	36 831 000
<b>Sum kortsiktig gjeld</b>		<b>26 242 000</b>	<b>48 364 000</b>
<b>Sum gjeld</b>		<b>26 242 000</b>	<b>48 364 000</b>
<b>SUM EGENKAPITAL OG GJELD</b>		<b>54 367 000</b>	<b>72 561 000</b>



## Brønnøysundregistrene

### ÅRSREGNSKAP FOR REGNSKAPSÅRET 2024 - GENERELL INFORMASJON

Journalnummer: 2025 655482

#### Enheten

Organisasjonsnummer: 986 400 990  
Organisasjonsform: Aksjeselskap  
Foretaksnavn: THERMO FISHER DIAGNOSTICS AS  
Forretningsadresse: Ullernchausséen 52  
0379 OSLO

#### Regnskapsår

Årsregnskapets periode: 01.01.2024 - 31.12.2024

#### Konsern

Morselskap i konsern: Nei

#### Regnskapsregler

Regler for små foretak benyttet: Nei  
Benyttet ved utarbeidelsen av årsregnskapet til selskapet: Regnskapslovens alminnelige regler

#### Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet: Petrus Van Der Zande  
Dato for fastsettelse av årsregnskapet: 19.06.2025

#### Revisjon

Årsregnskapet er utarbeidet av ekstern autorisert regnskapsfører: Ja  
Ekstern autorisert regnskapsfører har i løpet av regnskapsåret bistått ved den løpende regnskapsføringen eller utført andre tjenester for selskapet enn å utarbeide årsregnskapet: Ja

#### Grunnlag for avgivelse

År 2024: Årsregnskap er elektronisk innlevert.  
År 2023: Tall er hentet fra elektronisk innlevert årsregnskap fra 2024.

*Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.*

Brønnøysundregistrene, 10.07.2025



Organisasjonsnr: 986 400 990  
THERMO FISHER DIAGNOSTICS AS

## RESULTATREGNSKAP

<b>Beløp i: NOK</b>	<b>Note</b>	<b>2024</b>	<b>2023</b>
<b>RESULTATREGNSKAP</b>			
<b>Inntekter</b>			
Revenue from sales of products and services	2	126 185 000	132 903 000
<b>Sum inntekter</b>		<b>126 185 000</b>	<b>132 903 000</b>
<b>Kostnader</b>			
Raw materials and consumables used	3	102 238 000	109 055 000
Employee benefits expense	4	8 907 000	8 455 000
Depreciation and amortization expenses	5	1 147 000	347 000
Other operating expenses		8 899 000	12 134 000
<b>Sum kostnader</b>		<b>121 191 000</b>	<b>129 991 000</b>
<b>Driftsresultat</b>		<b>4 994 000</b>	<b>2 912 000</b>
<b>Finansinntekter og finanskostnader</b>			
Other intercompany finance income		1 736 000	1 406 000
<b>Sum finansinntekter</b>		<b>1 736 000</b>	<b>1 406 000</b>
Finance (expenses)		1 620 000	1 909 000
<b>Sum finanskostnader</b>		<b>1 620 000</b>	<b>1 909 000</b>
<b>Netto finans</b>		<b>116 000</b>	<b>-503 000</b>
<b>Resultat før skattekostnad</b>		<b>5 110 000</b>	<b>2 409 000</b>
Income tax expense	6	1 182 000	551 000
<b>Årsresultat</b>		<b>3 928 000</b>	<b>1 858 000</b>
<b>Overføringer og disponeringer</b>			
Transfers other equity	7	3 928 000	1 858 000
<b>Sum overføringer og disponeringer</b>		<b>3 928 000</b>	<b>1 858 000</b>





<b>Sum langsiktig gjeld</b>	<b>0</b>	<b>0</b>
<b>Kortsiktig gjeld</b>		
Trade payables	1 600 000	122 000
Other short-term debt	9 147 000	11 411 000
Payables to group companies 10	15 495 000	36 831 000
<b>Sum kortsiktig gjeld</b>	<b>26 242 000</b>	<b>48 364 000</b>
<b>Sum gjeld</b>	<b>26 242 000</b>	<b>48 364 000</b>
<b>SUM EGENKAPITAL OG GJELD</b>	<b>54 367 000</b>	<b>72 561 000</b>



Organisasjonsnr: 986 400 990  
THERMO FISHER DIAGNOSTICS AS

NOTEOPPLYSNINGER - SELSKAP - alle poster oppgitt i hele tall

Note  
1

#### Regnskapsprinsipper

The Financial Statements have been prepared in accordance with the Norwegian Accounting Act and generally accepted accounting principles.

Note  
0

Antall årsverk i regnskapsåret  
11.00

Sum Beløp

Balanseført verdi 31.12. Varige driftsmidler Immaterielle eiend.

#### Konsernregnskap

Morselskapet sitt navn

Forretningskontor for morselskapet

#### Begrunnelse for at datterselskap er utelatt fra konsolideringen

Samlet beløp - tilknyttet selskap Årets Fjorårets

Samlet beløp - foretak i samme konsern Årets Fjorårets

Samlet beløp - foretak i samme konsern Årets Fjorårets

Samlet beløp - felles kontrollert virksomhet Årets Fjorårets



Pantstillelse Beløp

Beholdning av egne aksjer Antall Pålydende Andel av aksjek.



To the General Meeting of Thermo Fisher Diagnostics AS

## Independent Auditor's Report

### Opinion

We have audited the financial statements of Thermo Fisher Diagnostics AS (the Company), which comprise the balance sheet as at 31 December 2024, the profit and loss statement and cash flow statement for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion the financial statements comply with applicable statutory requirements, and the financial statements give a true and fair view of the financial position of the Company as at 31 December 2024, and its financial performance and its cash flows for the year then ended in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway.

### Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company as required by relevant laws and regulations in Norway and the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Other Information

The Board of Directors and the Managing Director (management) are responsible for the information in the Board of Directors' report. The other information comprises information in the annual report, but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the information in the Board of Directors' report.

In connection with our audit of the financial statements, our responsibility is to read the Board of Directors' report. The purpose is to consider if there is material inconsistency between the Board of Directors' report and the financial statements or our knowledge obtained in the audit, or whether the Board of Directors' report otherwise appears to be materially misstated. We are required to report if there is a material misstatement in the Board of Directors' report. We have nothing to report in this regard.

Based on our knowledge obtained in the audit, it is our opinion that the Board of Directors' report

- is consistent with the financial statements and
- contains the information required by applicable statutory requirements.

### Responsibilities of Management for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Norwegian Accounting Act and accounting standards and practices generally accepted in Norway, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern. The financial statements use the going concern basis of accounting insofar as it is not likely that the enterprise will cease operations.

PricewaterhouseCoopers AS, Dronning Eufemias gate 71, Postboks 748 Sentrum, NO-0106 Oslo  
T: 02316, org. no.: 987 009 713 MVA, [www.pwc.no](http://www.pwc.no)  
Statsautoriserte revisorer, medlemmer av Den norske Revisorforening og autorisert regnskapsførerselskap



#### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. For further description of Auditor's Responsibilities for the Audit of the Financial Statements reference is made to: <https://revisorforeningen.no/revisjonsberetninger>

Oslo, 20 June 2025

**PricewaterhouseCoopers AS**

Berit Alstad

State Authorised Public Accountant

(This document is signed electronically)



 Securely signed with Brevio

Auditor's report

**Signers:**

<b>Name</b>	<b>Method</b>	<b>Date</b>
Alstad, Berit	BANKID	2025-06-23 13:17

**This document package contains:**

- Closing page (this page)
- The original document(s)
- The electronic signatures. These are not visible in the document, but are electronically integrated.



This file is sealed with a digital signature.  
The seal is a guarantee for the authenticity  
of the document.



Skatteetaten

Vår dato  
20.05.2019

Din/Deres dato  
20.03.2019

Saksbehandler  
Henning Stokke

800 80 000  
Skatteetaten.no

Din/Deres referanse  
Jørgen Viktil

Telefon  
800 80 000

Org.nr  
974761076

Vår referanse  
2019/5560226

Postadresse  
Postboks 9200 Grønland  
0134 OSLO

THERMO FISHER SCIENTIFIC NORWAY HOLDINGS AS  
c/o Life Technologies Postboks 114 Smestad  
0309 OSLO

## Tillatelse til å utarbeide årsberetning og årsregnskap på engelsk språk for Thermo Fisher Diagnostics AS, org.nr. 986 400 990

Vi viser til deres brev av 20. mars 2019 der det søkes om dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk for Thermo Fisher Diagnostics AS.

Skattedirektoratet gir på bakgrunn av en konkret helhetsvurdering Thermo Fisher Diagnostics AS dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk språk, jf. regnskapsloven § 3-4 tredje ledd. Dispensasjonen gjelder så lenge opplysningene som vedtaket baserer seg på ikke endres vesentlig.

Kopi av dette brevet må sendes Regnskapsregisteret i Brønnøysund sammen med årsregnskapet. Det påligger den regnskapspliktige å dokumentere ved dette brev at tillatelsen er gitt.

### Bakgrunn

Fra søknaden gjengis:

*Søknaden omfatter det norske selskapet Thermo Fisher Diagnostics AS (986400990). Selskapets virksomhet består av salg av medisinsk utstyr og materiell til farmasøytiske selskaper, sykehus og andre biotekniske selskaper. Thermo Fisher Diagnostics AS er del av Thermo Fisher Scientific Inc. som er konsernspiss og børsnotert i USA. Selskapet har 14 ansatte.*

*Thermo Fisher Diagnostics AS ble stiftet i 9. desember 2003. Selskapet kontrolleres av eneeier Oxoid International Ltd. Administrasjonen av selskapet gjøres i betydelig grad fra Glasgow UK. Selskapet vil utarbeide årsregnskap på engelsk og konsernets rapportennngsspråk er engelsk. Selskapets nåværende og fremtidige aksjonærer er profesjonelle investorer som opererer i et engelskspråklig forretningsmiljø, og som støtter at selskapet utarbeider årsregnskapet på engelsk. Selskapet vil utarbeide selskapsdokumenter på engelsk så langt dette er tillatt. Språket som benyttes i formell kommunikasjon er i hovedsak engelsk. Dette forutsettes ved nyansettelser i Thermo Fisher Scientific inc. konsernet.*



*Konsernets eiere, styremedlemmer og eksterne interessenter ønsker informasjon på engelsk. En rekke av selskapets interessenter behersker i begrenset grad norsk, herunder internasjonalt ansatte og internasjonale kreditorer, og vil således måtte oversette årsregnskapet til engelsk for å kunne ta stilling til dette.*

*Thermo Fisher Diagnostics har inngått vesentlige konserninterne avtaler med internasjonale selskaper i gruppen. Konsernets kunder vil i stor grad være internasjonale kunder. Selskapets eksterne kreditorer utgjør i hovedsak profesjonelle aktører som benytter engelsk som forretningspråk. Dette omfatter leverandører av finansielle tjenester samt leveranser av varer og tjenester til utvikling og drift av konsernets salgsvirksomhet av medisinsk utstyr.*

*For selskapet er det både tids- og kostnadskrevende å oversette regnskapet fra engelsk til norsk, og det fremstår derfor som en unødvendig byrde og konkurranseulempe å utarbeide årsregnskapet på norsk. Brukerne av regnskapsinformasjonen vil ikke bli negativt påvirket av at regnskapene blir avgitt kun på engelsk.*

#### **Skattedirektoratets vurdering**

Etter regnskapsloven § 3-4 tredje ledd skal "årsregnskapet og årsberetningen ... være på norsk. Departementet kan ved ... enkeltvedtak bestemme at årsregnskapet og/eller årsberetningen kan være på et annet språk."

I Ot. prp. nr. 42 (1997-1998) Om lov om årsregnskap m.v., er det uttalt følgende om regnskapslovens formål, jf. pkt. 1.1:

*"Regjeringen har som siktemål at regnskapsloven skal bidra til informative regnskaper for ulike grupper av regnskapsbrukere. Regnskapsbrukerne er dels investorer og kreditorer som tilfører kapital til foretakene, og dels andre grupper som har interesse av å vite hvordan foretaket drives, f.eks. de ansatte og lokalsamfunnet. Informasjonen til kapitalmarkedet skal gi grunnlag for riktig prising av finansielle objekter. Riktig prisdannelse på aksjer er en forutsetning for at ressursbruken i samfunnsøkonomien skal bli best mulig. Gode regnskaper vil også gjøre det vanskeligere for markedsdeltakere å ta ut spekulasjonsgevinster med basis i skjevt fordelt informasjon."*

Det fremgår således at et av hovedformålene med regnskapsloven er å bidra til "informative regnskaper for ulike grupper av regnskapsbrukere". Regnskapsbrukere vil omfatte, jf. uttalelsen i proposisjonen, blant andre investorer, kreditorer, ansatte og lokalsamfunnet.

Det er etter Skattedirektoratets vurdering derfor avgjørende ved vurdering av om dispensasjon fra kravet til å utarbeide årsregnskap og/eller årsberetning på norsk kan gis, at det ikke foreligger mulige brukere av regnskapsinformasjon som blir vesentlig berørt negativt ved en eventuell dispensasjon.

Som nevnt ovenfor er det er særlig hensynet til brukerne av regnskapsinformasjon som skal vurderes ved en dispensasjonssøknad. I denne vurderingen har Skattedirektoratet lagt vekt på at selskapet er heleid av



et utenlandsk selskap. I tillegg opererer selskapet i en internasjonal bransje, og arbeidsspråket er engelsk. Videre er det vektlagt at alle sentrale aktører og samarbeidspartnere innen denne bransjen behersker og benytter engelsk.

Vennligst oppgi vår referanse ved henvendelser i saken.

Med hilsen

Inger Helene Iversen  
seniorrådgiver  
Juridisk avdeling  
Skattedirektoratet

Henning Stokke

*Dokumentet er elektronisk godkjent og har derfor ikke håndskrevne signaturer.*



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

Thermo Fisher  
Diagnostics AS

Annual report and Financial Statements  
for the year ended 31 December 2024



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Board of Directors' report

Thermo Fisher Diagnostics AS (the Company) was incorporated in 2004 and is a wholly owned subsidiary of Oxoid International Ltd. Based in Altrincham, England. The ultimate parent is Thermo Fisher Scientific Inc.

The business address of Thermo Fisher Diagnostics AS is Ullernchausseen 52 0379, Oslo, Norway.

The directors present their annual report together with the audited annual accounts of the Company for the financial period ended 31 December 2024.

### Business areas

Thermo Fisher Diagnostics AS is part of the Specialty Diagnostics Group of Thermo Fisher Scientific and operates in three divisions:

- ImmunoDiagnostics division (IDD) develops, produces and markets innovative blood test systems ensuring correct diagnoses of blood samples and monitoring of allergy, asthma and autoimmune diseases.
- Microbiology division (MBD) sells and distributes Microbiology products for the clinical market (e.g. prepared culture media, rapid diagnostics test), pharmaceutical market (e.g. sterility testing, quality control) and food market (rapid culture methods, identification tests).
- Clinical diagnostics division (CDD) sells and distributes clinical diagnostic products and is product leader in drugs of abuse testing, sepsis diagnosis, quality control materials like molecular controls and laboratory automation.

### Research and Development activities

The company is not active in Research and Development and is not planning on incurring any significant Research and Development costs in the future.

### Objectives and Policies for Risk Management

It is Thermo Fisher Diagnostics AS' objective to assess risk on a regular basis. Activities that need to be performed from a risk perspective are laid out in corporate policies.

### Financial risk management

Currently Thermo Fisher Diagnostics AS has assessed the currency risk and has determined not to hedge these currency risks. These risks mainly result from positions in currencies outside the Euro zone. The Board of Directors has assessed that limited risk exists since the valuation of securities relates only to cash at the bank and in hand. The Board of Directors has assessed the interest rate risk and has determined not to enter financial derivatives. To manage credit risk customers are assessed for their credit worthiness.

### Competitive risk

The markets for our products and services are very competitive and price sensitive. Our competitors have significant financial, operational, sales and marketing resources, and experience in research and development. Our competitors could develop new technologies that compete with our products and services or even render our products and services obsolete. If a competitor develops superior technology or cost-effective alternatives to our products and services, our business could be seriously harmed. The markets for some of our products are also subject to specific competitive risks. These markets are highly price competitive. Our competitors have competed in the past by lowering prices on certain products. If they do so again, we may be forced to respond by lowering our prices and thereby reducing our revenues and profits. Failure to anticipate and respond to price competition may hurt our competitive position. Response would be Price Benchmarking competition and Strengthening Brands.



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Board of Directors' report

#### Economic risks

The global economy still has economic challenges. In the event of worsening economic conditions in the businesses or geographic areas in which we sell our products, and/or services, demand for our products, and/or services, could be reduced and result in a decrease in sales volume that could have a negative impact on our results of operations. Global credit and capital markets continue to experience volatility and disruption.

#### Funding risk

Our customers include researchers at pharmaceutical and biotechnology companies, academic institutions, government laboratories and private foundations. Fluctuations in the research and development budgets of these researchers and their organizations could have a significant effect on the demand for our products. Budgets may fluctuate due to mergers of pharmaceutical and biotechnology companies, site consolidations or relocations to other parts of the globe, spending priorities, general economic conditions and institutional and governmental budgetary policies. Response such as Analysis of economic developments; Diversifying customer segment portfolio.

#### Financial Position

The company has implemented policies that require appropriate credit checks on potential customers before a sale is made. The amount of exposure to any individual counterparty is subject to a limit, which is continuously reviewed by the senior management team.

#### Laws and regulations

A changing legislative and regulatory environment increases the cost of doing business, tax levels and the complexity of our operations. Response - Knowledge and awareness of regulations; Monitoring, review and reporting of changes; Operational procedure and guidance.

#### Financing and Investments

A changing legislative and regulatory environment increases the cost of doing business, tax levels and the complexity of our operations. Response - Knowledge and awareness of regulations; Monitoring, review and reporting of changes; Operational procedure and guidance.

#### Development in profit and loss, balance sheet and cash flows

The net profit of the Company for the financial year was NOK 3,927,850 (2023: NOK 1,857,528). The company paid dividends of NOK nil during the year (2023: NOK nil) and received dividends of NOK nil (2023: NOK nil). The directors recommend the net profit be allocated to retained earnings.

Total assets as at 31 December 2024 total NOK 54,367,012 (2023: NOK 72,561,325). The company has prospects of positive earnings going forward and given the positive equity and access to group funding the Company prepares the financial statements based on the going concern assumption.

Net cash outflow from operating activities was NOK 671,916 for 2024, Profit before income taxes was NOK 5,109,793. Cash flow from investments through acquisition was NOK nil.

Cash at year end was NOK 3,606,459.

#### Number of employees

The average number of employees in 2024 amounted to 11 (2023, 11). At year end, the actual number of employees was 11 (2023, 11).

Absence due to illness was recorded in operations as 0.4%, Illnesses supported with a doctor's note totaled 6 days (45 hours). Illnesses not supported with a doctor's note totaled 3 days (22.5 hours).



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Board of Directors' report

#### Directors' indemnification

The ultimate parent company, Thermo Fisher Scientific Inc. maintains liability insurance for its Directors and Officers. These indemnities are uncapped in amount (subject to certain exceptions) in relation to losses and liabilities which they may incur to third parties in the course of acting as a Director or Officer of the Company. The indemnity will continue for the benefit of Directors and Officers on an ongoing basis.

#### Working environment

Wages are adjusted to the position's demand for responsibility, skills and market wages. The Company provides remuneration based on the performance and results of the individual employee. The operation emphasizes being an attractive place to work and attracts the best employees. Thermo Fisher Diagnostics AS is engaged in developing and utilizing diversity in the organization both as regards sex, age, skills, and cultural background.

Thermo Fisher Diagnostics AS continuously works with monitoring and following up on health, environment, safety, and job satisfaction. Necessary control measures are documented, and the results evaluated. There have been no accidents or injuries in the workplace. The working environment is good.

#### Environmental Impact

Our mission is to enable our customers to make the world healthier, cleaner and safer. One way that we fulfill our Mission is by being a socially responsible community partner. Our giving strategy includes educational programmes, colleague donations and volunteering.

Our signature STEM education programs connect students and colleagues through hands on and team based activities that highlight our technologies, make connections to careers in STEM and demonstrate how our company impacts the world.

To promote the generous spirit of our colleagues, our Charitable Giving Program provides a platform that allows them to contribute to causes that they feel passionately about. Through the programme, employees can make direct donations to a charity of their choice, create a fundraiser - gathering greater support for a cause, or contribute to support a disaster relief campaign. Through our Employee Matching Gift program, we help employees make an even bigger impact by matching their contribution to eligible charities by 50%.

We feel it is important to support our community, throughout the year we encourage employees to take part in volunteering and charity events where our employees, together with our charity partners, take part in hands on volunteering.

The company is a part of Thermo Fisher Scientific Inc.'s global strategy to reduce our carbon footprint by 30% by 2030. As part of this global initiative, we are committed to reviewing and reducing greenhouse gas emissions. The impact on the environment is insignificant for Thermo Fisher Diagnostics AS.

#### The Transparency Act

The Transparency Act entered into force on 1 July 2022. The purpose of the act is to promote businesses' respect for human rights and decent working conditions, as well as ensure the public's access to information. Thermo Fisher Diagnostics AS is currently complying with the rulings and regulations of the Norwegian Transparency Act. Refer to the "Human Rights and Modern Slavery Transparency Act Statement", which is published on the group's website each year.



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS Board of Directors' report

### Outlook

The company believes its long-term prospects remain excellent given the attractive markets served, its industry leading position and proven growth strategy. It should be noted that there are always some risks when predicting the future but apart from inherent risk there are no other going concern risks for the company.

### Subsequent Events

There are no subsequent events to disclose.

**Oslo, 19th June 2025**

DocuSigned by:  
**PETRUS THOMAS ADRIANUS VAN DER ZANDE**  
844A9E4F466648D  
Petrus Van Der Zande  
Chair of the Board of Directors

DocuSigned by:  
**ANNE OMHOLT**  
06B93D1C8C534D5...  
Anne Omholt  
Member/General Manager

DocuSigned by:  
**Sara Maria Carrella**  
8DB7F883A4794AD  
Sara Maria Carrella  
Member



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Profit and loss statement

	Note	2024-12-31 NOK000	2023-12-31 NOK000
<b>REVENUE</b>			
Revenue from sales of products and services	2	126 185	132 903
Revenue		<u>126 185</u>	<u>132 903</u>
<b>OPERATING EXPENSES</b>			
Raw materials and consumables used	3	102 238	109 055
Employee benefits expense	4	8 907	8 455
Depreciation and amortization expenses	5	1 147	347
Other operating expenses		8 899	12 134
Total operating expenses		<u>121 191</u>	<u>129 991</u>
<b>Profit</b>		<b><u>4 994</u></b>	<b><u>2 912</u></b>
<b>FINANCIAL INCOME AND EXPENSES</b>			
Other intercompany finance income		1 736	1 406
Finance (expenses)		-1 620	-1 909
<b>Net finance income / (expense)</b>		<b><u>116</u></b>	<b><u>-503</u></b>
<b>Profit before tax</b>		<b>5 110</b>	<b>2 409</b>
Income tax expense	6	1 182	551
<b>Profit for the year</b>		<b><u>3 928</u></b>	<b><u>1 858</u></b>
<i>Transfers and allocations</i>			
Transfers other equity	7	3 928	1 858
Total transfers		<u>3 928</u>	<u>1 858</u>



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

### Thermo Fisher Diagnostics AS

#### Balance sheet

	Note	2024-12-31 NOK000	2023-12-31 NOK000
<b>Non-current assets</b>			
<b>Tangible Assets</b>			
Operating equipment and other fixed assets	5	5 421	813
Total fixed assets		<u>5 421</u>	<u>813</u>
<b>Financial assets</b>			
Deferred tax benefit	6	14 197	15 379
Total financial assets		<u>14 197</u>	<u>15 379</u>
<b>Total non-current assets</b>		<b><u>19 618</u></b>	<b><u>16 192</u></b>
<b>Current assets</b>			
Inventories	8	<u>818</u>	<u>292</u>
<b>Receivables</b>			
Accounts receivable		10 299	16 982
Receivable from group companies	10	19 804	34 447
Other receivables		222	370
Total receivables		<u>30 325</u>	<u>51 799</u>
Cash and cash equivalents	12	<u>3 606</u>	<u>4 278</u>
<b>Total current assets</b>		<b><u>34 749</u></b>	<b><u>56 369</u></b>
<b>Total assets</b>		<b><u>54 367</u></b>	<b><u>72 561</u></b>




DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6


## Thermo Fisher Diagnostics AS


### Balance sheet (continued)

	Note	2024-12-31 NOK000	2023-12-31 NOK000
<b>Equity and liabilities</b>			
<b>Share capital</b>			
Share capital	7, 11	100	100
Share premiums	7	200	200
Total owners' equity		<u>300</u>	<u>300</u>
<b>Retained equity</b>			
Other equity	7	27 825	23 897
Total retained equity		<u>27 825</u>	<u>23 897</u>
<b>Total equity</b>		<u><b>28 125</b></u>	<u><b>24 197</b></u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade payables		1 600	122
Other short-term debt		9 147	11 411
Payables to group companies	10	15 495	36 831
<b>Total liabilities</b>		<u><b>26 242</b></u>	<u><b>48 364</b></u>
<b>Total equity and liabilities</b>		<u><b>54 367</b></u>	<u><b>72 561</b></u>

Oslo, 19th June 2024

DocuSigned by:  
  
844A9E47466E48D...  
Petrus Van Der Zande  
Chair of the Board of Directors

DocuSigned by:  
  
06053D7C6C534D5...  
Anne Omholt  
Member/General Manager

DocuSigned by:  
  
80B7E883A4754AD...  
Sara Maria Carrella  
Member



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Cash flow statement

	Note	2024-12-31 NOK000	2023-12-31 NOK000
<b>Cash flow from operating activities</b>			
Result before tax		5 110	2 408
Depreciation	5	1 147	347
Change in inventories		-526	260
Change in accounts receivable		6 683	-4 185
Change in accounts payable		1 478	-711
Change in other current receivables and liabilities		3 284	3 036
Total cash flow from operating activities		<u>17 176</u>	<u>1 155</u>
<b>Cash flow from investing activities</b>			
Tangible fixed assets additions		-5 754	0
Change in cash pool		6 828	-599
Total cash flow from investing activities		<u>1 074</u>	<u>-599</u>
<b>Cash flow from financing activities</b>			
Change in Cash Pool		-18 922	0
<b>Net cash flow for the year</b>		<u><b>-672</b></u>	<u><b>556</b></u>
Cash and cash equivalents at 01.01		<u>4 278</u>	<u>3 722</u>
<b>Cash and cash equivalents at 31.12</b>	12	<u><b>3 606</b></u>	<u><b>4 278</b></u>



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Notes to financial statements

#### Note 1 - Accounting policies

The Financial Statements have been prepared in accordance with the Norwegian Accounting Act and generally accepted accounting principles.

##### 1.1 Use of estimates

The management has used estimates and assumptions that have affected assets, liabilities, incomes, expenses and information on potential liabilities in accordance with generally accepted accounting principles in Norway.

##### 1.2 Foreign currency translation

Transactions in foreign currency are converted at the rate at the transaction date. Monetary items in foreign currency are translated into Norwegian kroner using the exchange rate at the balance sheet date. Non-monetary items measured at historical rates expressed in foreign currency are translated into Norwegian kroner using the exchange rate at the transaction date. Non-monetary items measured at fair value expressed in foreign currency are translated at the exchange rate determined on the measurement date. Exchange rate fluctuations are recognized in the income statement during the accounting period under other financial items.

##### 1.3 Revenue recognition

Revenues from the sale of goods are recognized in the income statement once delivery has taken place and most of the risk and return has been transferred. Service revenue is recognized over the period services are performed.

##### 1.4 Income tax

The tax expense consists of the tax payable and changes to deferred tax. Deferred tax/tax assets are calculated on all differences between the book value and tax value of assets and liabilities. Deferred tax is calculated as 22% of temporary differences and the tax effect of tax losses carried forward. Deferred tax assets are recorded in the balance sheet when it is more likely than not that the tax assets will be utilised.

Taxes payable and deferred taxes are recognized directly in equity to the extent that they relate to equity transactions.

##### 1.5 Balance sheet Classification of Property, plant and equipment

Fixed assets are valued at cost, less depreciation and impairment losses. Long-term liabilities are recognized at nominal value.

Plant and equipment is capitalized and appreciated over the economic lifetime of the asset. Significant items of plant and equipment that consist of several material components with different lifetimes are broken down in order to establish different depreciation periods for the different components. Direct maintenance of plant and equipment is expensed on an ongoing basis under operating costs, while additions or improvements are added to the asset's cost price and depreciated in line with the asset. Plant and equipment is written down to the recoverable amount in the event of a fall in value that is not expected to be temporary. The recoverable amount is the higher of the net sales value and the value in use. Value in use is the present value of future cash flows related to the asset. The write-down is reversed when the basis for the write-down is no longer present.

##### 1.6 Balance sheet classification of current assets and current liabilities

Current assets and short term liabilities consist of receivables and payables due within one year. Other balance sheet items are classified as fixed assets / long term liabilities.

Current assets are valued at the lower of cost and fair value. Short-term liabilities are recognized at nominal value.



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Notes to financial statements (continued)

#### 1.7 Inventories

Inventories are recognized at the lowest of cost and net selling price. The net selling price is the estimated selling price in the case of ordinary operations minus the estimated completion, marketing and distribution costs. The cost is arrived at using the FIFO method and includes the costs incurred in acquiring the goods and the costs of bringing the goods to their current state and location.

#### 1.8 Accounts receivable and other receivables

Accounts receivable and other current receivables are recorded in the balance sheet at nominal value less provisions for doubtful accounts. Provisions for doubtful accounts are based on an individual assessment of the different receivables. For the remaining receivables, a general provision is estimated based on expected loss.

#### 1.9 Pensions

The entity has a collective pension insurance that covers all employees. The scheme is a contribution scheme. The year's pension premium, adjusted for any payment or deductions to the deposit fund, is recognized as pension cost. The entities pension scheme satisfies the requirements of the Act on Mandatory Occupational Pensions.

#### 1.10 Cash flow

The cash flow statement is presented using the indirect method. Cash and cash equivalents include cash, bank deposits and other short-term, highly liquid investments with maturities of three months or less.

### Note 2 - Revenue

		2024 NOK000	2023 NOK000
<b>City division</b>			
ImmunoDiagnostics	Product	5 272	6 229
ImmunoDiagnostics	Consumables	67 532	67 902
ImmunoDiagnostics	Service	1 945	1 958
Microbiology	Product	256	625
Microbiology	Consumables	36 550	35 543
Microbiology	Service	285	121
Clinical Diagnostics	Product	508	735
Clinical Diagnostics	Consumables	12 231	18 447
Clinical Diagnostics	Service	1 606	1 305
Other		0	38
		<u>126 185</u>	<u>132 903</u>
		2024 NOK000	2023 NOK000
<b>Geographical distribution</b>			
Nordics		126 185	132 903
		<u>126 185</u>	<u>132 903</u>



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Notes to financial statements (continued)

#### Note 3 - Intercompany transactions with group companies and associates

Main intercompany transactions in 2024 are listed as below.

	2024 NOK000	2023 NOK000	
B R A H M S GmbH	2 149	10 987	Sister
Cezanne S A S	66	18	Sister
Microgenics BV & Co KG	6 859	7 606	Sister
Oxoid Germany GmbH	18 809	13 050	Sister
Oxoid Limited	4 996	5 453	Parent
Phadia AB	63 467	64 018	Sister
Thermo Fisher Diagnostics AB	5	72	Sister
Thermo Fisher Diagnostics SAS	8	3	Sister
Thermo Fisher Scientific Oy	636	761	Sister
Trek Diagnostic Systems Limited	750	897	Sister
Thermo Fisher Diagnostics Limited	3	0	Sister
Thermo Fisher Diagnostics Aps	11	0	Sister
Thermo Fisher Diagnostics BV	4 479	0	Sister
	<u>102 238</u>	<u>102 865</u>	

The above intercompany transactions relate to intercompany purchases (costs of goods sold).

Other intercompany transactions are sale of goods, rental, management services, interest on intercompany loans and other financial costs.

#### Note 4 - Salary and personnel costs, employee information and audit fees

##### Salary and personnel costs

	2024 NOK000	2023 NOK000
Salaries	7 179	6 278
Payroll taxes	1 279	984
Pension costs	521	725
Other benefits	-72	468
	<u>8 907</u>	<u>8 455</u>

The company had 11 full time equivalents at 31 December 2024 (2023 11)

##### Pension

The company is liable to maintain an occupational pension scheme under the Mandatory Occupational Pensions Act. The company's pension schemes satisfy the requirements of this Act.

	2024 NOK000	2023 NOK000
<b>Remuneration to current General Manager</b>		
Salary	1 003	925
Other benefits	168	166
	<u>1 171</u>	<u>1 091</u>

No loan/guarantees have been granted to the chairman of the board or other related parties.



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Notes to financial statements (continued)

#### Audit fees

	2024 NOK000	2023 NOK000
Statutory audit fees	281	527
Total Audit fees	<u>281</u>	<u>527</u>

#### Note 5 - Tangible fixed assets

	Machinery and equipment NOK000	Operating equipment and other assets NOK000	Total NOK000
<b>Cost</b>			
Acquisition costs at the start of the year	11 893	202	12 095
Additions	5 754	0	5 754
As of December 31, 2024	<u>17 647</u>	<u>202</u>	<u>17 849</u>
<b>Depreciation</b>			
Accumulated depreciation	11 080	202	11 282
Depreciation for the year	1 147	0	1 147
As of December 31, 2024	<u>12 227</u>	<u>202</u>	<u>12 429</u>
<b>Net book value</b>			
As of December 31, 2024	<u>5 420</u>	<u>0</u>	<u>5 420</u>
As of December 31, 2023	<u>813</u>	<u>0</u>	<u>813</u>

The Machinery and Equipment addition related to an instrument purchased from the intercompany entity, Phadia AB.

The company uses linear amortization for all tangible assets. The useful economic lives are estimated to be:

Machinery and equipment	3 - 10 years
-------------------------	--------------



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Notes to financial statements (continued)

#### Note 6 - Income tax

	2024	2023
	NOK000	NOK000
<b>Temporary differences</b>		
Non-current assets	-2 802	-3 721
Receivables	0	-23
Accruals and provisions	-1 529	-724
Inventories	-252	-1 045
Tax Loss Carry Forward	-59 948	-64 391
Net temporary differences at 31.12	<u>-64 531</u>	<u>-69 904</u>

	2024	2023
	NOK000	NOK000
<b>Calculation of the tax base for the year:</b>		
Profit before tax	5 109	2 408
Permanent differences	263	96
Change in temporary differences	-930	156
Loss carried forward - utilization	-4 442	-2 660
Tax base of the year	<u>0</u>	<u>0</u>

	2024	2023
	NOK000	NOK000
<b>Tax expense for the year comprises of:</b>		
Change in deferred tax asset	<u>1 182</u>	<u>551</u>

The deferred tax liability is calculated at 22% which is the 2024 tax rate.

#### Note 7 - Equity

	Share capital NOK000	Premium shares NOK000	Retained Earnings NOK000	Total NOK000
<b>2024</b>				
Equity at the start of the year	100	200	23 897	24 197
Equity 01.01	<u>100</u>	<u>200</u>	<u>23 897</u>	<u>24 197</u>
Profit	0	0	3 928	3 928
<b>Equity 31.12</b>	<u>100</u>	<u>200</u>	<u>27 825</u>	<u>28 125</u>

#### Note 8 - Inventories

	2024	2023
	NOK000	NOK000
Finished goods	818	292
<b>Total</b>	<u>818</u>	<u>292</u>
Total cost of goods in the period	102 238	109 055
Book value of inventory provided as security	<u>0</u>	<u>0</u>



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Notes to financial statements (continued)

#### Note 9 - Receivables and liabilities

	2024 NOK000	2023 NOK000
Assets with maturity later than one year	0	0
Long-term liabilities with maturity later than 5 years	0	0
	<u>0</u>	<u>0</u>

None of the company's liabilities are secured by the company's assets.  
The company has no guarantee obligations.

#### Note 10 - Related parties

	NOK000
<b>2024 Receivables</b>	
Fisher Scientific A/S	6
FEI Electron Optics BV	223
Brahms GmbH	1 129
Avocado Research Chemicals Ltd	142
Intercompany cash pool - receivables	18 304
Total 2024 receivables	<u>19 804</u>

	NOK000
<b>2023 Receivables</b>	
Fisher Scientific A/S	45
FEI Electron Optics BV	37
Brahms GmbH	3 708
FEI Europe BV	42
Phadia AB	5 452
FEI SAS	32
Intercompany cash pool - receivables	25 132
Total 2023 receivables	<u>34 448</u>

	NOK000
<b>2024 Payables</b>	
Thermo Fisher Scientific Inc.	6
Thermo Fisher Diagnostics BV	577
Thermo Electron (Management Services) Ltd	322
Oxoid Limited	1 361
Microgenics BV and Co KG	261
Oxoid Deutschland GmbH	6 176
Trek Diagnostic Systems Ltd	28
Phadia AB	5 232
Thermo Electron Corporation	11
Thermo Fisher Scientific	1 522
Total 2024 payables	<u>15 496</u>



DocuSign Envelope ID: D82F58F4-3FB7-4A08-B87B-110886619AD6

## Thermo Fisher Diagnostics AS

### Notes to financial statements (continued)

	NOK000
<b>2023 Payables</b>	
Thermo Fisher Scientific Inc.	5
Thermo Fisher Scientific Oy	329
Thermo Electron (Management Services) Ltd	4
Brahms GmbH	369
Oxoid Limited	2 804
Microgenics BV and Co KG	706
Oxoid Deutschland GmbH	6 899
Trek Diagnostic Systems Ltd	110
Phadia AB	6 683
Intercompany cash pool - debt	18 922
Total 2023 payables	<u>36 831</u>

Thermo Fisher Diagnostics AS has not provided any guarantees for other concerned companies.

The company has a cash pool arrangement with Thermo Fisher Financial Services BV who is the owner of the 'BMG' cash pool; the balance of which in 2024 was NOK 1.

The company has a cash pool arrangement with Thermo Fisher Scientific Inc who is the owner of the 'Nordea' cash pool; the balance of which in 2024 was NOK 17,359,068.

The company has a cashpool arrangement with Life Technologies Finance Ltd, who is the owner of the In House Banking account; the balance of which in 2024 was NOK 944,677.

### Note 11 - Share capital and shareholder information

	Number of shares	Nominal value NOK000	Carrying amount NOK000
<b>2024</b>			
<b>The share capital consists of:</b>			
Ordinary Shares	1 000	100	100 000

All shares carry the same rights in the company.

Thermo Fisher Diagnostics AS is wholly owned by Oxoid International Ltd.

The chief executive officer and board members do not own any shares in the company.

The ultimate parent company is Thermo Fisher Scientific Inc. which is based in Waltham, MA USA. Consolidated accounts of Thermo Fisher Scientific Inc., which include Thermo Fisher Diagnostics AS can be received at 168 Third Avenue, Waltham, MA USA 02451.

### Note 12 - Cash

	2024 NOK000	2023 NOK000
<b>Employee Tax Withholding Accounts:</b>		
Bank Deposits for employee withholding tax	<u>3 606</u>	<u>4 278</u>